To suggest that the discovery of targetable driver mutations in many patients with advanced adenocarcinoma of the lung has completely transformed the work-up and therapeutic options for this disease would not be hyperbole. Although not curative, smallmolecule tyrosine kinase inhibitors directed at oncogene-addicted tumors have led to significantly improved response rates compared with cytotoxic chemotherapy, with often manageable toxicities and better tolerance. However, the absence of reliable clinical predictors has made molecular testing essential to ensure that patients receive the proper medical management. We outline the many recent advances with regard to diagnosis and treatment of oncogene-addicted advanced nonsquamous non-small-cell lung cancer.
INTRODUCTION
Lung cancer is the leading cancer killer worldwide, and for many years, despite intense effort, scientific and therapeutic advances were slow to develop. By early last decade, standard cytotoxic agents had clearly reached a plateau in achieving responses in metastatic disease, with median survival a disappointing 10 months. 1 However, shortly thereafter, the discovery that small-molecule tyrosine kinase inhibitors (TKIs) could have significant activity in adenocarcinoma of the lung ushered in a new age of targeted therapies that continues to expand and widen options for patients with advanced lung cancer [2] [3] [4] [5] (Fig 1) . This article reviews the dramatic advances in targeted therapies for advanced adenocarcinoma of the lung (Table 1) . Although efforts are under way to identify molecular targets for immunotherapy drugs, such as immune checkpoint inhibitors, this review limits discussion to specific molecular mutations that predict response to small-molecule-targeted therapies. Likewise, the identification and therapeutic targeting of genomic drivers in squamous lung cancer and small-cell lung cancer continue to lag behind the therapeutic advances in adenocarcinoma and thus are not addressed here.
To firmly establish a lung cancer diagnosis, tissue confirmation is a necessity. With consideration that the majority of patients who present with lung cancer are in the advanced stages and thus are not candidates for surgical resection, tissue diagnosis often rests on small biopsy samples and/or cytology specimens. 5 Because squamous carcinoma of the lung harbors a different spectrum of molecular abnormalities, has different recommended chemotherapeutic regimens, and remains without approved specific targeting agents, a diagnosis of non-small-cell lung carcinoma (NSCLC) is insufficient for appropriate therapeutic selection. Therefore, a strong recommendation is that the pathologist classify NSCLC to a more-specific histotype whenever feasible. 5 At the same time, a conservative material for potential molecular diagnostic testing that may give the patient treatment options with targeted therapies. Given the importance of testing the tumor for actionable mutations, the pathologist must be actively involved in the work-up, both in selecting the correct specimens for testing and making sure that small biopsy samples are appropriately managed. In many hospitals, pathologists and oncologists need to work together to develop algorithms for molecular testing in patients with advanced adenocarcinoma of the lung.
MOLECULAR TESTING
Current guidelines recommend that any patient with advanced or metastatic lung cancer undergo molecular testing before initiation of therapy unless the disease is actively threatening the patient's health 6 (Fig 2) . Clinical features, such as light or never-smoking status or East Asian ancestry, although suggestive, are not enough to avoid mutation testing in any patient with advanced adenocarcinoma. Many hospitals will run epidermal growth factor receptor (EGFR) mutation analysis as well as anaplastic lymphoma receptor tyrosine kinase (ALK) and ROS1 testing when adenocarcinoma is diagnosed. If the patient's tumor is triple negative for these three drivers, further assays can be done if tissue remains available. Some centers will assay for KRAS mutations, which if positive, are generally mutually exclusive for other mutations. The rationale to withhold treatment until molecular study results are available is based on a number of clinical trials that have shown that patients with EGFR-and ALK-mutated lung cancers have superior response rates and improved progressionfree survival with targeted therapy compared with conventional cytotoxic therapy. 3, 7 The benefit of targeted therapies over chemotherapy has been so well established in oncogene-addicted lung cancer that clinicians must explain to patients that the brief delay in initiating therapy is small compared with the clinical benefit of starting a targeted therapy should a mutation be discovered. That being said, molecular test turnaround time should be , 10 days for optimal treatment. Many patients with advanced lung cancer, however, often have biopsy samples that are inadequate for molecular studies. In these situations, the question facing the treating physician is whether to try to rebiopsy or to initiate chemotherapy. Currently, there is increasing interest in the use of liquid biopsies, which look at either cell-free DNA or circulating tumor cells to establish diagnosis and monitor disease. Liquid biopsies 
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Abbreviations: ALK, anaplastic lymphoma receptor tyrosine kinase; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; MET, mesenchymal-epithelial transition factor; RET, rearranged during transfection.
theoretically mitigate the need for invasive procedures, but data are lacking to confidently assert that these tests should be used for diagnosis. 8 These technologies are mostly being used in assessing for acquired resistance in patients who have a mutation initially detected in tissue. 9, 10 Of note, core biopsies are not mandatory for mutational analysis; cytology often can yield excellent material for analysis.
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EGFR EGFR is a transmembrane receptor of the ErbB family. Mutations in this receptor activate downstream proteins involved in cellular survival and proliferation. In 2004, the activity of gefitinib, a small-molecule TKI, was proven to be based on the presence of activating mutations in the receptor and not on amplification. 2 Many subsequent studies confirmed that patients with the common exon 19 deletions (60% of patients) and the exon 21 L858R mutation (25%) have significantly better responses to first-generation TKIs than to multiagent chemotherapy. 7, 12 Not all EGFR mutations confer sensitivity to TKIs: Exon 20 deletions are almost always resistant; thus, the specific EGFR mutation must be reported so that the correct therapy can be selected. 13 The toxicities of these agents tend to be manageable and are different from what is seen with cytotoxic chemotherapy. Rash and diarrhea can be problematic, and may necessitate dose reductions. Doxycycline can be helpful in alleviating the severity of rash. Because patients who respond likely will receive medication for a long time, finding an effective dose that they can tolerate is far more important than trying to get as close to the ideal starting dose. In addition, once patients begin to progress, if the progression is minimal and the patient asymptomatic, often the continuation of TKI therapy beyond progression (and the addition of localized radiation to an oligometastatic site) can put off medication switching for 6 to 9 months. 14 The addition of other therapies to TKI therapy, such as the angiogenesis inhibitor bevacizumab or chemotherapy with pemetrexed, has shown some promise but requires further study. 15, 16 Of note, EGFR-mutated lung cancer seems less responsive to immune checkpoint blockade.
17
Targeted therapy for EGFR-mutated lung cancer, while often leading to prolonged response, inevitably leads to acquired resistance. Rebiopsy studies have shown that 60% of the time the cause is the T790 mutation. Therapy specifically targeted to this mutation is now available; the third-generation TKI osimertinib has significant activity, with a response rate of 61% and median progression-free survival of 9.6 months. 18 The availability of serum-or urine-based assays has made screening for the T790 mutation for radiographic progression easier, but if a noninvasive assay does not reveal a T790 mutation, an invasive biopsy must be performed because other mechanisms of acquired resistance, such as small-cell transformation or mesenchymal-epithelial transition factor (MET) overexpression, can be seen. The use of osimertinib in the frontline setting is being studied to see whether the development of the T790 mutation can be prevented or whether it merely directs a different evolution of alternative mutations that eventually cause acquired resistance.
ALK
The echinoderm microtubule-associated protein-like 4 (EML4) -ALK translocation was first described in 2007 and has been found to be present in approximately 5% of NSCLC cases. 19 The translocation leads to the constitutive activation of the ALK gene with resultant downstream activation of cell division and growth pathways. This mutation is more commonly seen in younger patients who are never smokers, and CNS metastases are a frequent clinical problem. 20 Crizotinib, an oral inhibitor of ALK as well as MET, has significant clinical activity and was approved by the Food and Drug Administration in 2011 for use in patients whose tumors harbor an ALK translocation. Much like the story with EGFR, the targeting of ALK translocation, when present, provides a statistically significant improvement in progression-free survival and overall response rate compared with cytotoxic chemotherapy. In patients previously treated with platinum doublet chemotherapy, crizotinib showed a significant benefit over cytotoxic chemotherapy. 21 The results led to a frontline randomized phase III trial that compared pemetrexed with either carboplatin or cisplatin versus crizotinib 250 mg twice a day. 3 The crizotinib group fared better in terms of progression-free survival (10.9 v 7 months; hazard ratio of progression to death, 0.45; objective response rate, 74% v 45% with chemotherapy). Although crizotinib often had adverse effects of diarrhea and nausea, symptom burden from lung cancer was reduced and better quality-of-life scores favored crizotinib over chemotherapy.
As with all targeted therapies, patients eventually acquire resistance and must be switched to other treatments. The story of acquired resistance to crizotinib is more complicated than that of EGFR. Approximately one third of patients develop a new mutation in the ALK tyrosine kinase domain or amplification of the ALK fusion gene. In the remaining patients, a variety of other mechanisms have been reported. 22 However, a number of agents have been developed and approved for second-line disease. Ceritinib achieved response rates of 58% in patients who had previously been treated with crizotinib, with a median duration of response of 8.2 months, but responses seemed independent of the underlying mechanism of molecular resistance. 23 Alectinib is another new oral smallmolecule inhibitor of ALK. In patients previously treated with crizotinib and many who had also received chemotherapy, alectinib had an overall response rate of 50% and a median duration of response of 11.2 months. 24 The agent has significant activity in patients with CNS metastases, which is encouraging (CNS disease control rate, 83%; duration of response, 10.3 months). Brigatinib is a new experimental ALK inhibitor that shows significant activity in crizotinib-treated patients with ALK mutations and with preclinical evidence that suggests that it might be effective against a number of secondary ALK mutations that contribute to acquired resistance. 25, 26 Should chemotherapy need to be used after clinical progression while receiving ALK inhibitors, however, pemetrexed-based regimens show significant activity.
ROS1
ROS1 was first described in 2008. 27 Like ALK, it tends to be seen in younger patients with little to no tobacco exposure. Also like ALK, a number of fusion partners have been identified, all of which leave the tyrosine kinase constitutively active and drive downstream phosphatidylinositol 3-kinase, mitogen-activated protein kinase (MAPK), and signal transducer and activator of transcription 3 activity and cellular growth and transformation. No gold standard for making the diagnosis currently exists; fluorescence in situ hybridization (FISH), immunohistochemistry and polymerase chain reaction, and next-generation sequencing (NGS) have been used. One strategy for both ALK and ROS1 translocations is to screen with immunohistochemistry and confirm with FISH testing. ROS1-mutated tumors are sensitive to crizotinib; response rates are in the range of 80% in patients previously treated with chemotherapy. 28 The median duration of response is 17.6 months, and the median progression-free survival is 19 months. 4 No difference in responsiveness to crizotinib has been seen with regard to the identity of the particular fusion partners. Like ALK, ROS1-mutated tumors are sensitive to pemetrexed chemotherapy. 29 Unlike some of the other driver-mutated lung cancers, other mutations have been identified as coexisting with ROS1, such as EGFR, KRAS, and BRAF. 30 The molecular causes of acquired resistance are being elucidated, and they involve mutations in the tyrosine kinase domain as well as epithelial-to-mesenchymal transformation and activation of bypass pathways.
31,32
KRAS KRAS mutations are the single most common identifiable mutation in adenocarcinoma of the lung, have been an intractable therapeutic hurdle, and remain essentially undruggable. Attempts to target downstream molecules in the MAPK pathway have been toxic as well as disappointing. These mutations often arise in smokers and carry a worse prognosis. 33 KRAS mutations often are mutually exclusive with other driver mutations; thus, some groups have advocated the testing of KRAS status in triplenegative tumors (ie, negative for ALK, ROS1, EGFR) and only proceed with other mutation testing if the tumor is KRAS wild type. KRAS-mutated lung cancers also are more likely to have a high mutational burden and thus benefit more from immune checkpoint therapy. In a subgroup analysis of patients treated with nivolumab monotherapy, patients with KRAS-mutated cancer were not necessarily more likely than patients with KRAS wild type to respond; however, they had a significantly longer progression-free survival (11.8 v 2.3 months).
OTHER TARGETABLE DRIVERS
Mutations in the BRAF gene, which lead to activation of the MAPK pathway, have been shown to be oncogenic drivers across a number of malignancies, including NSCLC. The mutation can be found in 1% to 3% of adenocarcinomas and are roughly split between V600 and non-V600 mutations. 35 Unlike ALK and EGFR, these mutations are seen in greater frequency in heavy smokers, although V600 is more likely than non-V600 to be found in light smokers. 36 Dabrafenib had shown some early efficacy in a phase II trial, and owing to the data from melanoma where combination therapy was shown to be more effective, a trial of dabrafenib and trametinib was undertaken in patients with previously treated advanced V600-positive BRAF-mutated adenocarcinoma. 37 The overall response rate was 63%, with 4% of patients achieving a complete remission and 60% a partial response. The median duration of treatment with both agents was 10.6 months; approximately one third of the patients received therapy beyond 12 months. The combination had toxicities: 50% of patients had grade 3 to 4 toxicities, but with dose modification, the majority remained in the study. The question of whether upfront targeted therapy in treatment-naive BRAF-mutated adenocarcinoma provides a superior response rate is being actively studied. HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 Human epidermal growth factor receptor 2 (HER2) mutations are found in approximately 1% to 2% of lung adenocarcinomas. These mutations tend to be found in younger female nonsmokers and are almost always mutually exclusive with other driver mutations. 42 Earlier trials suggested a possible role for trastuzumab added to chemotherapy, although patients were selected on the basis of HER2 staining and not on mutation. 43 Since then, HER2 mutations have been recognized to confer activity in lung cancer differently from those found in breast cancer. They are specifically exon 20 insertions rather than amplification, and the actionable mutation often is present without amplification. 44 Trastuzumab and afatanib both have shown meaningful clinical activity, although much of the data have been collected retrospectively. 45 RET RET (rearranged during transfection) translocations are found in 1% to 2% of patients with adenocarcinoma of the lung. A number of fusion partners have been described. These mutations tend to arise in younger patients with earlier nodal spread and more-aggressive biologic activity. 46 A number of methods have been used for detection, including reverse transcription polymerase chain reaction and NGS. Limited data exist on the efficacy of targeted therapies; however, some clinical activity has been demonstrated. 47, 48 Vandetanib achieved an objective response rate of 47%, the median progression-free survival of 4.7 months was less than has generally been seen in other oncogene-addicted lung cancers.
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In conclusion, the identification of multiple driver mutations behind the carcinogenesis of adenocarcinoma of the lung, coupled with the development of active and well-tolerated oral TKIs, has completely transformed the treatment of this common lethal disease. Although not curative, many patients can count on TKIs for prolonged control of disease and a good quality of life. Continued elucidation of the mechanisms that lead to acquired resistance are hoped to allow the development of pharmacologic strategies that either prevent or circumvent the proliferation of drug-resistant clones.
For patients to fully benefit, however, they must be tested. Pathologists must be involved in the work-up and ensure that biopsy samples are mindfully used so an adequate portion of the procedure material can be submitted for mutational testing. Appropriate use of procured material lessens the need for additional invasive biopsies. Liquid biopsies-cell-free DNA and circulating tumor cells-may help to further reduce the need for invasive procedures, but additional studies that address reproducibility and correlation with tissue findings are needed as this methodology develops.
